Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00478751
Status:
COMPLETED
Last Update Posted:
2024-04-30
First Post:
2007-05-24
Brief Title:
Impact of Long Wavelength Ultraviolet UVA and Visible Light on Melanocompetent Skin
Sponsor:
Henry Ford Health System
Organization:
Henry Ford Health System
Study Overview
Official Title:
Impact of Long Wavelength UVA and Visible Light on Melanocompetent Skin
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determine the impact and the threshold of long wavelength UVA and visible light on immediate and delayed pigment production of melanocompetent individuals
The study basically wants to understand what types of light make us tan
The study basically wants to understand what types of light make us tan
Detailed Description:
1 Background
A great deal is known about the impact of UVB and short wavelength UVA on pigmentation Most sunscreens only protect against UVB and portions of UVA However it is not clear if other components of the spectrum of sunlight not currently protected by sunscreens are capable of eliciting pigmentation Very little is known about the impact of long wavelength UVA and visible light on the time course to pigmentation the quality of pigmentation and durations of this change in pigment if any This has implications on the use of sunscreens to inhibit pigment production and the treatment of conditions that are aggravated by sun exposure such as melasma
The impact of visible light 400-700 nm on melanogenesis was studied by Porges et al in 1988 The threshold dose for IPD with visible light was between 40 and 80 Jcm2 while the threshold dose for persistent pigmentation was greater than or equal to 80 Jcm2 1
2 Study objective
-To determine the impact of long wavelength UVA and visible light on immediate and delayed pigment production of melanocompetent individuals
3 Study design
Patient to serve as their own control Patient must be melanocompetent skin phototypes IV to VI with no history of vitiligo melasma or photosensitivity The symmetric back or forearm will be used as a control of the irradiated area Two phototherapy delivery system will be developed for the study 1 A targeted visible light phototherapy device 2 A targeted long wavelength UVA device
Pigmentation will be assessed by visual exam fluorescent and reflectance spectroscopy at 6 timepoints immediately after irradiation 30 minutes after exposure 1 hour after exposure 1 day after exposure 1 week after exposure and 2 weeks after exposure
A great deal is known about the impact of UVB and short wavelength UVA on pigmentation Most sunscreens only protect against UVB and portions of UVA However it is not clear if other components of the spectrum of sunlight not currently protected by sunscreens are capable of eliciting pigmentation Very little is known about the impact of long wavelength UVA and visible light on the time course to pigmentation the quality of pigmentation and durations of this change in pigment if any This has implications on the use of sunscreens to inhibit pigment production and the treatment of conditions that are aggravated by sun exposure such as melasma
The impact of visible light 400-700 nm on melanogenesis was studied by Porges et al in 1988 The threshold dose for IPD with visible light was between 40 and 80 Jcm2 while the threshold dose for persistent pigmentation was greater than or equal to 80 Jcm2 1
2 Study objective
-To determine the impact of long wavelength UVA and visible light on immediate and delayed pigment production of melanocompetent individuals
3 Study design
Patient to serve as their own control Patient must be melanocompetent skin phototypes IV to VI with no history of vitiligo melasma or photosensitivity The symmetric back or forearm will be used as a control of the irradiated area Two phototherapy delivery system will be developed for the study 1 A targeted visible light phototherapy device 2 A targeted long wavelength UVA device
Pigmentation will be assessed by visual exam fluorescent and reflectance spectroscopy at 6 timepoints immediately after irradiation 30 minutes after exposure 1 hour after exposure 1 day after exposure 1 week after exposure and 2 weeks after exposure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None